BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 17697391)

  • 21. Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer.
    Nowacka-Zawisza M; Brys M; Romanowicz-Makowska H; Kulig A; Krajewska WM
    Pathol Int; 2008 May; 58(5):275-81. PubMed ID: 18429825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The molecular pathology of hereditary breast cancer.
    Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
    Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer.
    Lewis AG; Flanagan J; Marsh A; Pupo GM; Mann G; Spurdle AB; Lindeman GJ; Visvader JE; Brown MA; Chenevix-Trench G;
    Breast Cancer Res; 2005; 7(6):R1005-16. PubMed ID: 16280053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular and pathological characterization of inherited breast cancer.
    Borg A
    Semin Cancer Biol; 2001 Oct; 11(5):375-85. PubMed ID: 11562180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1 does not paint the inactive X to localize XIST RNA but may contribute to broad changes in cancer that impact XIST and Xi heterochromatin.
    Pageau GJ; Hall LL; Lawrence JB
    J Cell Biochem; 2007 Mar; 100(4):835-50. PubMed ID: 17146760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation.
    DelloRusso C; Welcsh PL; Wang W; Garcia RL; King MC; Swisher EM
    Mol Cancer Res; 2007 Jan; 5(1):35-45. PubMed ID: 17259345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of BRCA1 and BRCA2 in male breast cancers and gynecomastias.
    Bernard-Gallon DJ; Déchelotte PJ; Le Corre L; Vissac-Sabatier C; Favy DA; Cravello L; De Latour MP; Bignon YJ
    Anticancer Res; 2003; 23(1B):661-7. PubMed ID: 12680164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
    Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
    Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
    Chen X; Truong TT; Weaver J; Bove BA; Cattie K; Armstrong BA; Daly MB; Godwin AK
    Hum Mutat; 2006 May; 27(5):427-35. PubMed ID: 16619214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
    Evans DG; Young K; Bulman M; Shenton A; Wallace A; Lalloo F
    Clin Genet; 2008 Apr; 73(4):338-45. PubMed ID: 18312450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
    Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
    Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family.
    Palanca Suela S; Esteban Cardeñosa E; Barragán González E; Oltra Soler S; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Bolufer Gilabert P;
    Breast Cancer Res Treat; 2008 Nov; 112(1):63-7. PubMed ID: 18060491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A recurrent mutation in PALB2 in Finnish cancer families.
    Erkko H; Xia B; Nikkilä J; Schleutker J; Syrjäkoski K; Mannermaa A; Kallioniemi A; Pylkäs K; Karppinen SM; Rapakko K; Miron A; Sheng Q; Li G; Mattila H; Bell DW; Haber DA; Grip M; Reiman M; Jukkola-Vuorinen A; Mustonen A; Kere J; Aaltonen LA; Kosma VM; Kataja V; Soini Y; Drapkin RI; Livingston DM; Winqvist R
    Nature; 2007 Mar; 446(7133):316-9. PubMed ID: 17287723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line.
    Pignatelli M; Cocca C; Santos A; Perez-Castillo A
    Oncogene; 2003 Aug; 22(35):5446-50. PubMed ID: 12934104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons learned from BRCA1 and BRCA2.
    Zheng L; Li S; Boyer TG; Lee WH
    Oncogene; 2000 Dec; 19(53):6159-75. PubMed ID: 11156530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity.
    Ostrow KL; McGuire V; Whittemore AS; DiCioccio RA
    Cancer Genet Cytogenet; 2004 Sep; 153(2):177-80. PubMed ID: 15350310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA1 is differentially expressed in human tumor cells.
    Meng QH; Yuan RQ; Goldberg ID; Rosen EM; Fan SJ
    Shi Yan Sheng Wu Xue Bao; 2001 Mar; 34(1):55-64. PubMed ID: 12549011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1 gene in breast cancer.
    Rosen EM; Fan S; Pestell RG; Goldberg ID
    J Cell Physiol; 2003 Jul; 196(1):19-41. PubMed ID: 12767038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer.
    Karppinen SM; Erkko H; Reini K; Pospiech H; Heikkinen K; Rapakko K; Syväoja JE; Winqvist R
    Eur J Cancer; 2006 Oct; 42(15):2647-52. PubMed ID: 16930991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors.
    Winter SL; Bosnoyan-Collins L; Pinnaduwage D; Andrulis IL
    BMC Cancer; 2007 May; 7():85. PubMed ID: 17511879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.